Michela Staderini
Florence, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network.
Journal: Frontiers in oncology
Published: February 10, 2023
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 11, 2021
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.
Journal: Leukemia & lymphoma
Published: August 11, 2020
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Journal: Hematological oncology
Published: August 07, 2020
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients.
Journal: European journal of haematology
Published: October 09, 2019
Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation.
Journal: Case reports in hematology
Published: June 11, 2019
New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Journal: Clinical chemistry and laboratory medicine
Published: July 18, 2015
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
Journal: Leukemia & lymphoma
Published: December 24, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026